Ron Bentsur
Chairman & CEO at Nuvectis Pharma Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 2 boards, counting each seat separately. Longest: Nuvectis Pharma Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Nuvectis Pharma Inc. June 11, 202695.5%
-
Beyond Air Inc. November 22, 202490.0%
-
Beyond Air Inc. March 8, 202488.1%
-
Nuvectis Pharma Inc. June 16, 202398.4%
-
Beyond Air Inc. March 9, 202387.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 2026 | Nuvectis Pharma Inc. | Open-market purchase | +12,500 | $20.00 | $250,000 |
| Jan 6, 2026 | Nuvectis Pharma Inc. | Grant or award | +150,000 | — | — |
| Nov 5, 2025 | Nuvectis Pharma Inc. | Open-market purchase | +5,000 | $5.72 | $28,600 |
| Jan 2, 2025 | Nuvectis Pharma Inc. | Grant or award | +250,000 | — | — |
| Dec 24, 2024 | Nuvectis Pharma Inc. | Open-market purchase | +4,500 | $4.65 | $20,925 |
| Nov 15, 2024 | Nuvectis Pharma Inc. | Open-market purchase | +20,000 | $4.92 | $98,400 |
| May 14, 2024 | Nuvectis Pharma Inc. | Open-market purchase | +1,940 | $6.74 | $13,076 |
| May 10, 2024 | Nuvectis Pharma Inc. | Open-market purchase | +2,000 | $6.40 | $12,800 |
| Mar 18, 2024 | Nuvectis Pharma Inc. | Open-market purchase | +5,000 | $10.29 | $51,450 |
| Oct 10, 2023 | Nuvectis Pharma Inc. | Open-market purchase | +640 | $11.08 | $7,091 |
| Oct 9, 2023 | Nuvectis Pharma Inc. | Open-market purchase | +830 | $11.19 | $9,288 |
| Oct 6, 2023 | Nuvectis Pharma Inc. | Open-market purchase | +250 | $11.27 | $2,818 |
| Oct 5, 2023 | Nuvectis Pharma Inc. | Open-market purchase | +1,400 | $11.09 | $15,526 |
| Oct 4, 2023 | Nuvectis Pharma Inc. | Open-market purchase | +1,820 | $10.95 | $19,929 |
| Aug 16, 2023 | Nuvectis Pharma Inc. | Open-market purchase | +115 | $15.15 | $1,742 |
Questions about Ron Bentsur
What boards is Ron Bentsur on?
Ron Bentsur sits on the boards of Beyond Air Inc. and Nuvectis Pharma Inc.
What company is Ron Bentsur the CEO of?
Ron Bentsur is Chairman & CEO of Nuvectis Pharma Inc.
How long has Ron Bentsur served on boards?
Our records show at least 8 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.